Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Coramitug · 1 trial · 1 indication
Measured as ratio.
Measured as milliliter per minute per centimeter cube (mL/min/cm\^3).
Measured as percentage (%).
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | The cohort includes participants that will be evaluated for the cardiac uptake of 89Zr coramitug. |
| Cohort 2 | EXPERIMENTAL | The cohort includes participants to evaluate the sink effect (if observed in cohort 1) and also evaluate competitive binding between 89Zr-coramitug and different dose levels of coramitug. |
| Name | Type | Description |
|---|---|---|
| Coramitug | DRUG | Coramitug will be administered intravenously |
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female. * Age greater than or equal to (≥) 60 years or a...
Coramitug is an investigational small molecule being developed for transthyretin amyloid cardiomyopathy, a condition in which abnormal amyloid deposits accumulate in heart tissue. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Coramitug is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker NVO. The company is conducting a Phase 1 clinical trial to evaluate the drug's distribution and effects in people with ATTR amyloidosis.
Coramitug is designed to interact with amyloid deposits in heart tissue, as studied through PET/CT imaging in a clinical trial. The drug's mechanism involves targeting these deposits to assess their distribution and effects, though the specific molecular target has not been disclosed.
Coramitug is in Phase 1 clinical development. The ongoing trial, NCT07448623, is a controlled, open-label study recruiting participants in the Netherlands. As an investigational drug, it has not received FDA approval and remains in early-stage testing.
Coramitug is being studied in one active Phase 1 clinical trial, NCT07448623, titled 'A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.' The trial is recruiting 14 participants aged 60 years and older in the Netherlands.
Coramitug is not the same as tafamidis. Coramitug is a distinct investigational small molecule being developed by Novo Nordisk for transthyretin amyloid cardiomyopathy, while tafamidis is a separately approved treatment for the same condition. No alternative names for Coramitug have been identified.